Erasca Inc (ERAS)

Shares of Erasca Inc (ERAS) dropped by 11.38% from $2.24 to $1.99 in the trading on Tuesday, November 28, 2023. The reason why ERAS is down today is due to the company's program updates, particularly regarding its SEACRAFT-2 Phase 3 trial for Naporafenib Plus Trametinib and its THUNDERBBOLT-1 Phase 1 trial for ERAS-801. Investors may have been concerned about the trial details, including the patient population and comparator arm in SEACRAFT-2, as well as the need for additional data for ERAS-801. Additionally, the company's decision to deprioritize certain programs and focus on more promising initiatives could have contributed to the stock's decline.